Literature DB >> 10880752

Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117).

A Blair1, H J Sutherland.   

Abstract

A hierarchy of progenitor cells is thought to exist in human acute myeloid leukemia (AML), with only the most primitive cells capable of proliferating to maintain the malignant clone. To further characterize this AML cell hierarchy, we evaluated the coexpression of CD34 and c-kit (CD117) on cells that are capable of long-term proliferation in vitro and in vivo.AML cells were sorted for coexpression of CD34 and c-kit (CD117) using two c-kit monoclonal antibodies (mAbs), clones 95C3 and 104D2. Sorted subfractions were evaluated for the ability to produce colony-forming units (CFU) for up to 8 weeks in suspension culture (SC) and for the capacity to repopulate NOD/SCID mice. When expression of c-kit on blood cells from 19 AML patients at diagnosis was compared using both mAbs, expression defined by 104D2 (34% +/- 6% c-kit(+)) was somewhat higher than that defined using 95C3 (18% +/- 4%). AML cells were sorted for coexpression of CD34 and c-kit using both c-kit mAbs, and the subfractions were assayed in vitro and in vivo. Whereas the majority of AML blast cells lacked expression of CD34, most AML cells capable of proliferating to produce CFU after 4 to 8 weeks in SC were CD34(+)/c-kit(-). Cultures of sorted CD34(+)/c-kit(-) cells, supplemented with steel factor, were composed of a large proportion (18% to 87%) of CD34(+)/c-kit(+) cells after 1 week, suggesting that either c-kit expression was upregulated or CD34(+)/c-kit(+) cells were produced. Moreover, the CD34(+)/c-kit(-) subfraction was found to be capable of responding to steel factor alone to produce CFU after 4 weeks in SC. In most AML patients tested (11/15), the only sorted subfraction capable of engrafting NOD/SCID mice was CD34(+)/c-kit(-). The CD34(+)/c-kit(+) subfraction from only 2 of the 15 patients and CD34(-) cells from 3 patients also engrafted the NOD/SCIDs. Only the CD34(+)/c-kit(+) subfraction of normal bone marrow engrafted. These studies suggest that primitive AML cells capable of long-term proliferation in vitro and NOD/SCID repopulation differ from primitive normal progenitor cells in their lack of surface expression of c-kit.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880752     DOI: 10.1016/s0301-472x(00)00155-7

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  39 in total

Review 1.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 2.  A primitive cell origin for B-cell precursor ALL?

Authors:  C V Cox; A Blair
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

Review 3.  Cancer stem cells: lessons from leukaemia.

Authors:  D Bonnet
Journal:  Cell Prolif       Date:  2005-12       Impact factor: 6.831

Review 4.  GPCRs in stem cell function.

Authors:  Van A Doze; Dianne M Perez
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

5.  p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.

Authors:  K P Ng; Q Ebrahem; S Negrotto; R Z Mahfouz; K A Link; Z Hu; X Gu; A Advani; M Kalaycio; R Sobecks; M Sekeres; E Copelan; T Radivoyevitch; J Maciejewski; J C Mulloy; Y Saunthararajah
Journal:  Leukemia       Date:  2011-06-24       Impact factor: 11.528

Review 6.  Right on target: eradicating leukemic stem cells.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

7.  Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.

Authors:  Gang G Wang; Martina P Pasillas; Mark P Kamps
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 8.  Regulating the leukaemia stem cell.

Authors:  Michael L Cleary
Journal:  Best Pract Res Clin Haematol       Date:  2009-12       Impact factor: 3.020

9.  Tumor stem cells: A new approach for tumor therapy (Review).

Authors:  Min Meng; Xin-Han Zhao; Qian Ning; Lei Hou; Guo-Hong Xin; Li-Feng Liu
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

Review 10.  Stem cells and cancer: an overview.

Authors:  Kevin M Sales; Marc C Winslet; Alexander M Seifalian
Journal:  Stem Cell Rev       Date:  2007-12       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.